A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases

A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases

Abstract Background Several bone-seeking radionuclides have been developed for palliation of metastatic bone pain since 1956, however, so far radium-223 dichloride is the first and only Food and Drug Administration (FDA) approved targeted alpha therapy for metastatic castration-resistant prostate ca...

Full description

Bibliographic Details
Main Authors: Zin W. Myint, Riham El Khouli, Bryan Lemieux, Donglin Yan, William H. St. Clair, Xiaoqi Liu, Charles A. Kunos
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Cancer
Subjects:
Metastatic castration resistant prostate cancer with bone met
Bone pain
Bone seeking radionuclides
Pain response
Analgesic consumption
Patient reported outcome
Online Access:https://doi.org/10.1186/s12885-022-09496-2

Internet

https://doi.org/10.1186/s12885-022-09496-2

Similar Items